for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Integra Lifesciences Holdings Corp

IART.OQ

Latest Trade

51.25USD

Change

-0.47(-0.91%)

Volume

147,572

Today's Range

51.00

 - 

51.72

52 Week Range

34.21

 - 

64.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
51.72
Open
51.41
Volume
147,572
3M AVG Volume
10.44
Today's High
51.72
Today's Low
51.00
52 Week High
64.23
52 Week Low
34.21
Shares Out (MIL)
84.27
Market Cap (MIL)
4,358.50
Forward P/E
27.84
Dividend (Yield %)
--

Next Event

Q3 2020 Integra Lifesciences Holdings Corp Earnings Release

Latest Developments

More

Integra Lifesciences Reports Q2 Revenue Of $258.7 Mln

Integra Lifesciences Says On July 14, Co Entered Into An Amendment To Sixth Amended & Restated Credit Agreement

Integra Lifesciences Holdings Sees Q2 2020 Revenue Of $254 Mln To $256 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Integra Lifesciences Holdings Corp

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.

Industry

Scientific & Technical Instr.

Contact Info

1100 CAMPUS ROAD

PRINCETON, NJ

08540

United States

+1.609.2750500

https://www.integralife.com/

Executive Leadership

Stuart M. Essig

Independent Chairman of the Board

Peter J. Arduini

President, Chief Executive Officer, Director

Carrie L. Anderson

Chief Financial Officer, Executive Vice President

Glenn G. Coleman

Chief Operating Officer, Executive Vice President

Lisa Evoli

Executive Vice President, Chief Human Resources Officer

Key Stats

2.29 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

1.2K

2018

1.5K

2019

1.5K

2020(E)

1.3K
EPS (USD)

2017

1.940

2018

2.420

2019

2.740

2020(E)

2.083
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.14
Price To Book (MRQ)
3.23
Price To Cash Flow (TTM)
39.33
Total Debt To Equity (MRQ)
115.06
LT Debt To Equity (MRQ)
114.23
Return on Investment (TTM)
-0.11
Return on Equity (TTM)
-0.10

Latest News

Latest News

BRIEF-Integra Lifesciences Holdings Sees Q2 2020 Revenue Of $254 Mln To $256 Mln

* INTEGRA LIFESCIENCES ANNOUNCES PRELIMINARY SECOND QUARTER REVENUE RESULTS; WILL HOST SECOND QUARTER 2020 FINANCIAL RESULTS CONFERENCE CALL ON AUGUST 10, 2020

BRIEF-Integra Lifesciences Announces Positive Clinical Results For Integra Bilayer Wound Matrix

* INTEGRA LIFESCIENCES ANNOUNCES POSITIVE CLINICAL RESULTS FOR INTEGRA® BILAYER WOUND MATRIX (IBWM) Source text for Eikon: Further company coverage:

BRIEF-Integra Lifesciences Reports Q1 Adjusted Earnings Per Share $0.48

* INTEGRA LIFESCIENCES REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Integra Lifesciences Board Approved Temporary Reductions In Base Salaries Of Executive Officers

* INTEGRA LIFESCIENCES HOLDINGS CORP - ON APRIL 16, 2020, BOARD APPROVED TEMPORARY REDUCTIONS IN BASE SALARIES OF COMPANY'S NAMED EXECUTIVE OFFICERS

BRIEF-Integra Lifesciences Sees Q1 2020 Revenue $352 Mln To $354 Mln

* INTEGRA LIFESCIENCES ANNOUNCES PRELIMINARY FIRST QUARTER REVENUE RESULTS AND PROVIDES AN UPDATE ON COVID-19 IMPACT; WILL HOST FIRST QUARTER 2020 FINANCIAL RESULTS CONFERENCE CALL ON MAY 7, 2020

BRIEF-Integra Lifesciences Launches Amnioexcel Plus Placental Allograft Membrane

* INTEGRA LIFESCIENCES LAUNCHES AMNIOEXCEL® PLUS PLACENTAL ALLOGRAFT MEMBRANE Source text for Eikon: Further company coverage:

BRIEF-Integra LifeSciences Reports Q4 Adjusted Earnings Per Share Of $0.68

* INTEGRA LIFESCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES 2020 FINANCIAL GUIDANCE

Integra gets FDA warning letter for Boston plant

Medical device maker Integra Lifesciences Holdings Corp said on Monday it had received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in Boston.

Integra gets FDA warning letter for Boston plant

Medical device maker Integra Lifesciences Holdings Corp said on Monday it had received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in Boston.

BRIEF-Integra Lifesciences Prices Public Offering Of Common Stock

* INTEGRA LIFESCIENCES PRICES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Integra LifeSciences Announces Proposed Public Offering Of Common Stock

* INTEGRA LIFESCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Integra Lifesciences Announces Amendment And Extension Of Credit Facility

* INTEGRA LIFESCIENCES ANNOUNCES AMENDMENT AND EXTENSION OF CREDIT FACILITY

BRIEF-Integra Lifesciences Reports Q1 Adjusted Earnings Per Share $0.58

* INTEGRA LIFESCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Integra LifeSciences Says CEO's 2017 Compensation Was $7.1 Mln

* INTEGRA LIFESCIENCES HOLDINGS CORP SAYS CEO PETER J. ARDUINI'S 2017 TOTAL COMPENSATION WAS $7.1 MILLION VERSUS $7 MILLION IN 2016 – SEC FILING Source: (https://bit.ly/2HdNFnd) Further company coverage:

BRIEF-Integra Lifesciences Holdings Reports Q4 EPS Of $0.56

* INTEGRA LIFESCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-Integra Lifesciences Q4 Adjusted Earnings Per Share $0.64

* INTEGRA LIFESCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-Integra Lifesciences Announces Preliminary Q4 Earnings Per Share View $0.55, Revenue View $351.0

* - ORGANIC REVENUE GROWTH IN Q4 IS EXPECTED TO BE ABOUT 5.5%, ABOVE COMPANY'S IMPLIED GUIDANCE OF ABOUT 4%

BRIEF-Capital Research Global Investors Reports 11.1 Pct Passive Stake In Integra Lifesciences As Of Nov 30

* CAPITAL RESEARCH GLOBAL INVESTORS REPORTS 11.1 PERCENT PASSIVE STAKE IN INTEGRA LIFESCIENCES HOLDINGS CORP AS OF NOVEMBER 30 - SEC FILING Source text: (http://bit.ly/2jb88l1) Further company coverage:

BRIEF-Integra Lifesciences Q3 adjusted earnings per share $0.45

* Integra Lifesciences reports third quarter 2017 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up